Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032
Overview
The Australia Pharmacogenetic Testing in Psychiatry depression Market is expected to reach a 33.30 USD Billion by 2032 and is projected to grow at a CAGR of 16.08% from 2025 to 2032.
Revenue, 2024 (USD Billion)
15.28
Forecast, 2032 (USD Billion)
33.30
CAGR, 2024 - 2032
16.08%
Report Coverage
Australia
Australia Pharmacogenetic Testing in Psychiatry depression Market 2018-2032 USD Billion
Australia Pharmacogenetic Testing in Psychiatry depression Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 15.28 USD Billion
- Projected Market Size (2032): 33.30 USD Billion
- CAGR (2025-2032): 16.08%
Key Findings of Australia Pharmacogenetic Testing in Psychiatry depression Market
- The Australia Pharmacogenetic Testing in Psychiatry depression Market was valued at 15.28 USD Billion in 2024.
- The Australia Pharmacogenetic Testing in Psychiatry depression Market is likely to grow at a CAGR of 16.08% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Saliva in Sample Segment accounted for the largest share of the market with a revenue of 9.98 USD Billion
- The fastest growing segment CYP2C19 in Genes Segment grew Fastest with a CAGR of 20.97% during the forecast period from 2024 to 2032.
Australia Pharmacogenetic Testing in Psychiatry depression Market Scope
Australia Pharmacogenetic Testing in Psychiatry depression Market Segmentation & Scope
Drug Type
- Vitamins/Nutraceuticals
- Recreational Drugs
- Over-The-Counter Medications
- Prescription Drugs
Genes
- COMT
- MTHFR
- SLC6A4
- CYP3A4
- HLA-A
- HTR2A/C
- Others
- HLA-B
- CYP2D6
- CYP2C9 AND VKORC1
- CYP2C19
Type
- Array-Based Tests
- Whole Genome Sequencing
Sample
- Blood
- Saliva
Distribution Channel
- Direct-To-Customer Services
- Mail-Order Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
End User
- Others
- Research Centres And Academic Institutes
- Healthcare Providers
- Pharmaceutical & Biotechnology Companies
Application
- Clinical Practice
- Drug Development
Australia Pharmacogenetic Testing in Psychiatry depression Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2020 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 15.28 USD Billion |
| Market Value in 2032 | 33.30 USD Billion |
| CAGR (2025-2032) | 16.08% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Drug Type,Genes,Type,Sample,Distribution Channel,End User,Application |
Regional Insights:
-
Leading Market (2024-2032): Australia, leading in terms of revenue 15.28 USD Billion in 2024
- Key Country: Australia, leading in terms of revenue with value of 15.28 USD Billion in 2024.
Segments and Scope
-
Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Drug Type
- Prescription Drugs is the largest segment in Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 6.86 USD Billion in the year 2024.
- Recreational Drugs is the Fastest growing segment in Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 16.53 % in forecast period 2025-2032.
-
Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Genes
- CYP2C19 is the largest segment in Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 3.43 USD Billion in the year 2024.
- CYP2C19 is the Fastest growing segment in Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 20.97 % in forecast period 2025-2032.
-
Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Type
- Whole Genome Sequencing is the largest segment in Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 9.66 USD Billion in the year 2024.
- Whole Genome Sequencing is the Fastest growing segment in Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 16.61 % in forecast period 2025-2032.
-
Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Sample
- Saliva is the largest segment in Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 9.98 USD Billion in the year 2024.
- Saliva is the Fastest growing segment in Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 16.63 % in forecast period 2025-2032.
-
Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Distribution Channel
- Retail Pharmacies is the largest segment in Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 6.45 USD Billion in the year 2024.
- Hospital Pharmacies is the Fastest growing segment in Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 16.27 % in forecast period 2025-2032.
-
Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032, By End User
- Pharmaceutical & Biotechnology Companies is the largest segment in Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 6.46 USD Billion in the year 2024.
- Pharmaceutical & Biotechnology Companies is the Fastest growing segment in Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 17.26 % in forecast period 2025-2032.
-
Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Application
- Drug Development is the largest segment in Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 8.88 USD Billion in the year 2024.
- Drug Development is the Fastest growing segment in Australia Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 16.71 % in forecast period 2025-2032.
Australia Pharmacogenetic Testing in Psychiatry depression Market Company Share Analysis
| Company Name |
|
||
| Millennium Health | |||
| Myriad Genetics, Inc. | |||
| PerkinElmer Inc. | |||
| Illumina, Inc. | |||
| Thermo Fisher Scientific Inc. | |||
Australia Pharmacogenetic Testing in Psychiatry depression Market Geographical Sales Distribution, 2018-2032 USD Billion
Australia Pharmacogenetic Testing in Psychiatry depression Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The Australia Pharmacogenetic Testing in Psychiatry depression Market is segmented based on Segmentation Drug Type,Genes,Type,Sample,Distribution Channel,End User,Application.
Australia Pharmacogenetic Testing in Psychiatry depression Market was valued at USD 15.28(Revenue in USD Billion) in 2020.
Australia Pharmacogenetic Testing in Psychiatry depression Market is projected to grow at a CAGR of 16.08% during the forecast period of 2024 to 2032.
The Saliva segment is expected to dominate the Australia Pharmacogenetic Testing in Psychiatry depression Market, holding a largest market share of 9.98 USD Billion in 2024
Australia Pharmacogenetic Testing in Psychiatry depression Market Scope
Australia Pharmacogenetic Testing in Psychiatry depression Market Segmentation & Scope
Drug Type
- Vitamins/Nutraceuticals
- Recreational Drugs
- Over-The-Counter Medications
- Prescription Drugs
Genes
- COMT
- MTHFR
- SLC6A4
- CYP3A4
- HLA-A
- HTR2A/C
- Others
- HLA-B
- CYP2D6
- CYP2C9 AND VKORC1
- CYP2C19
Type
- Array-Based Tests
- Whole Genome Sequencing
Sample
- Blood
- Saliva
Distribution Channel
- Direct-To-Customer Services
- Mail-Order Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
End User
- Others
- Research Centres And Academic Institutes
- Healthcare Providers
- Pharmaceutical & Biotechnology Companies
Application
- Clinical Practice
- Drug Development
Frequently Asked Questions
The Australia Pharmacogenetic Testing in Psychiatry depression Market is segmented based on Segmentation Drug Type,Genes,Type,Sample,Distribution Channel,End User,Application.
Australia Pharmacogenetic Testing in Psychiatry depression Market was valued at USD 15.28(Revenue in USD Billion) in 2020.
Australia Pharmacogenetic Testing in Psychiatry depression Market is projected to grow at a CAGR of 16.08% during the forecast period of 2024 to 2032.
The estimated market value of the Australia Pharmacogenetic Testing in Psychiatry depression Market for final year is USD 33.30 (USD Billion).
Australia Pharmacogenetic Testing in Psychiatry depression Market Company Profiling
Frequently Asked Questions
The Australia Pharmacogenetic Testing in Psychiatry depression Market is segmented based on Segmentation Drug Type,Genes,Type,Sample,Distribution Channel,End User,Application.
Australia Pharmacogenetic Testing in Psychiatry depression Market was valued at USD 15.28(Revenue in USD Billion) in 2020.
Australia Pharmacogenetic Testing in Psychiatry depression Market is projected to grow at a CAGR of 16.08% during the forecast period of 2024 to 2032.
The estimated market value of the Australia Pharmacogenetic Testing in Psychiatry depression Market for final year is USD 33.30 (USD Billion).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.